2024
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. Journal Of Hepatology 2024, 81: 895-910. PMID: 38908436, DOI: 10.1016/j.jhep.2024.06.016.Peer-Reviewed Original ResearchAcute-on-chronic liver failureChronic liver diseaseLiver disease progressionToll-like receptorsLiver diseasePortal hypertensionLiver failureDisease progressionLiver injuryImmune systemEnd-stage liver diseaseRelease of pro-inflammatory cytokinesInnate immune cellsFlares of inflammationDysfunctional immune systemInflammasome activationPro-inflammatory stateNuclear factor kappa BPro-inflammatory cytokinesAdaptive immune systemFactor kappa BSystemic inflammationLiver parenchymal cellsWhite adipose tissueImmune cells
2023
Bioactive signalling lipids as drivers of chronic liver diseases
Kaffe E, Tisi A, Magkrioti C, Aidinis V, Mehal W, Flavell R, Maccarrone M. Bioactive signalling lipids as drivers of chronic liver diseases. Journal Of Hepatology 2023, 80: 140-154. PMID: 37741346, DOI: 10.1016/j.jhep.2023.08.029.Peer-Reviewed Original ResearchConceptsChronic liver diseaseLiver diseasePrevalent chronic liver diseaseBioactive lipidsPotential therapeutic targetG protein-coupled receptorsProtein-coupled receptorsTherapeutic targetPoly-unsaturated fatty acidsMalignant transformationPotent modulatorEnergy homeostasisDiseaseCell proliferationSignaling lipidsTissue repairReceptorsFatty acidsMultiple cellular functionsLipidsBioactive roleBioactive signaling lipidsInflammationProgression
2019
1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model
Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseWeight loss medicationsNonalcoholic steatohepatitisBariatric surgeryWeight lossClinical characteristicsLiver diseaseObesity managementEffective treatmentDisease programsAverage age 55Meal replacement therapySurgical weight lossWeight loss optionsAlanine aminotransferase levelsChronic liver diseaseFatty liver diseaseObstructive sleep apneaManagement of patientsCare of patientsLimited efficacy dataClinical care modelsLiver disease modelAverage weight lossHepatology clinic
2013
The Immunopathogenesis of Cirrhosis
Gao B, Friedman S, Mehal W. The Immunopathogenesis of Cirrhosis. 2013, 413-424. DOI: 10.1007/978-3-319-02096-9_28.Peer-Reviewed Original ResearchHepatocellular carcinomaProgressive liver injuryChronic liver diseaseNatural killer cellsImmune cell subsetsAltered hepatic functionInnate immune responseWound healing responseViral hepatitisLiver injuryFibrosis progressionKiller cellsLiver diseaseAutoimmune diseasesCell subsetsChronic injuryHepatic fibrosisFibrogenic responseFibrosis resolutionHepatic functionHepatic parenchymaVascular remodelingImmune responseHepatocellular apoptosisBlood flow
2007
The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis
Mehal W, Friedman S. The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007, 111-121. DOI: 10.1007/978-1-59745-518-3_10.Peer-Reviewed Original ResearchHepatic fibrosisChronic liver diseaseRole of inflammationWound healing responseViral hepatitisLiver diseaseFibrosis progressionAutoimmune diseasesChronic injuryLiver fibrosisCellular sourceFibrosisExtracellular matrixDiseaseRealistic expectationsUbiquitous responseMajor advancesTranscriptional eventsHepatitisInflammationPatientsPathophysiologyPathogenesisInjuryLiver